

Haematologica  
HAEMATOL/2016/160564  
Version 4

Monitoring of multiple myeloma by quantification of recurrent mutations  
in serum

Even Holth Rustad, Eivind Coward, Emilie R Skytøen, Kristine Misund,  
Toril Holien, Therese Standal, Magne Børset, Vidar Beisvag, Ola  
Myklebost, Leonardo A Meza-Zepeda, Hong Yan Dai, Anders Sundan,  
and Anders Waage

Disclosures: The study received grants from the Norwegian University of Science of Technology, The Research Council of Norway (grant 218241), The Norwegian Cancer Society (grant 145753), The Central Norwegian Regional Health Authority, the South-Eastern Norwegian Regional Health Authority and the Kristian Gerhard Jebsen Foundation. Anders Waage has been paid honoraria from Celgene and Amgen, has been paid to consult for Celgene, Amgen and Novartis, and had received research funding from Amgen. Anders Sundan has been paid to consult for Celgene. The remaining authors report no potential conflicts of interest.

Contributions: EHR, AW, KM and AS conceived the study. EHR, EC, ERS, KM, TH, OM, VB, LAMZ and HYD established the methods and carried out laboratory and bioinformatics analyses. EHR, EC, ERS, TH, TS, KM, MB, AS and AW interpreted the data. EHR and AW drafted the manuscript, which was completed after input from all authors.